Manipulation of CD98 resolves type 1 diabetes in nonobese diabetic mice

Journal of Immunology

Volumn 188, Issue 5, 2012, Pages 2227-2234

  Lian, Gaojian ^a   Arimochi, Hideki ^a   Kitamura, Akiko ^a   Nishida, Jun ^a   Li, Shigen ^a   Kishihara, Kenji ^a   Maekawa, Yoichi ^a   Yasutomo, Koji ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD98 ANTIGEN; CD98HC ANTIBODY; CD98HC ANTIGEN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG TARGETING; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD98 HEAVY CHAIN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYCLOPHOSPHAMIDE; DIABETES MELLITUS, TYPE 1; FEMALE; GROWTH INHIBITORS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, SCID; MICE, TRANSGENIC; RATS; RATS, WISTAR;

EID: 84863169105     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1102586     Document Type: Article

References (27)

1. Castellino, F., and R. N. Germain. 2006. Cooperation between CD4+ and CD8+ T cells: when, where, and how. Annu. Rev. Immunol. 24: 519-540.
2. Lehuen, A., J. Diana, P. Zaccone, and A. Cooke. 2010. Immune cell crosstalk in type 1 diabetes. Nat. Rev. Immunol. 10: 501-513.
3. Carreno, B. M., and M. Collins. 2002. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu. Rev. Immunol. 20: 29-53. (Pubitemid 34293419)
4. Keir, M. E., M. J. Butte, G. J. Freeman, and A. H. Sharpe. 2008. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26: 677-704. (Pubitemid 351600389)
5. Watts, T. H. 2005. TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 23: 23-68. (Pubitemid 40563164)
6. Sugamura, K., N. Ishii, and A. D. Weinberg. 2004. Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat. Rev. Immunol. 4: 420-431. (Pubitemid 38745554)
7. Stadinski, B., J. Kappler, and G. S. Eisenbarth. 2010. Molecular targeting of islet autoantigens. Immunity 32: 446-456.
8. Shoda, L. K., D. L. Young, S. Ramanujan, C. C. Whiting, M. A. Atkinson, J. A. Bluestone, G. S. Eisenbarth, D. Mathis, A. A. Rossini, S. E. Campbell, et al. 2005. A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 23: 115-126. (Pubitemid 41169282)
9. Tsai, S., A. Shameli, and P. Santamaria. 2008. CD8+ T cells in type 1 diabetes. Adv. Immunol. 100: 79-124.
10. van Belle, T. L., K. T. Coppieters, and M. G. von Herrath. 2011. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol. Rev. 91: 79-118.
11. Bach, J. F., and D. Mathis. 1997. The NOD mouse. Res. Immunol. 148: 285-286. (Pubitemid 27435910)
12. Cantor, J. M., M. H. Ginsberg, and D. M. Rose. 2008. Integrin-associated proteins as potential therapeutic targets. Immunol. Rev. 223: 236-251. (Pubitemid 351986185)
13. Verrey, F., E. I. Closs, C.A. Wagner, M. Palacin, H. Endou, and Y. Kanai. 2004. CATs and HATs: the SLC7 family of amino acid transporters. Pflugers Arch. 447: 532-542. (Pubitemid 38258215)
14. Yan, Y., S. Vasudevan, H. T. Nguyen, and D. Merlin. 2008. Intestinal epithelial CD98: an oligomeric andmultifunctional protein. Biochim. Biophys. Acta 1780: 1087-1092.
15. Komada, H., A. Imai, E. Hattori, M. Ito, H. Tsumura, T. Onoda, M. Kuramochi, M. Tani, K. Yamamoto, M. Yamane, et al. 2006. Possible activation of murine T lymphocyte through CD98 is independent of interleukin 2/interleukin 2 receptor system. Biomed. Res. 27: 61-67.
16. Cantor, J., M. Slepak, N. Ege, J. T. Chang, and M. H. Ginsberg. 2011. Loss of T cell CD98 H chain specifically ablates T cell clonal expansion and protects from autoimmunity. J. Immunol. 187: 851-860.
17. Tarbell, K. V., L. Petit, X. Zuo, P. Toy, X. Luo, A. Mqadmi, H. Yang, M. Suthanthiran, S. Mojsov, and R. M. Steinman. 2007. Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice. J. Exp. Med. 204: 191-201. (Pubitemid 46148769)
18. Hu, C. Y., D. Rodriguez-Pinto, W. Du, A. Ahuja, O. Henegariu, F. S. Wong, M. J. Shlomchik, and L. Wen. 2007. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J. Clin. Invest. 117: 3857-3867. (Pubitemid 350224095)
19. Cantor, J., C. D. Browne, R. Ruppert, C. C. Féral, R. Fässler, R. C. Rickert, and M. H. Ginsberg. 2009. CD98hc facilitates B cell proliferation and adaptive humoral immunity. Nat. Immunol. 10: 412-419.
20. Petty, H. R., R. G. Worth, and R. F. Todd, III. 2002. Interactions of integrins with their partner proteins in leukocyte membranes. Immunol. Res. 25: 75-95. (Pubitemid 34155250)
21. Tsurudome, M., and Y. Ito. 2000. Function of fusion regulatory proteins (FRPs) in immune cells and virus-infected cells. Crit. Rev. Immunol. 20: 167-196. (Pubitemid 30645019)
22. Miyamoto, Y. J., J. S. Mitchell, and B. W. McIntyre. 2003. Physical association and functional interaction between beta1 integrin and CD98 on human T lymphocytes. Mol. Immunol. 39: 739-751. (Pubitemid 36078367)
23. Nguyen, H. T., G. Dalmasso, L. Torkvist, J. Halfvarson, Y. Yan, H. Laroui, D. Shmerling, T. Tallone, M. D'Amato, S. V. Sitaraman, and D. Merlin. 2011. CD98 expression modulates intestinal homeostasis, inflammation, and colitis-associated cancer in mice. J. Clin. Invest. 121: 1733-1747.
24. Bach, J. F., and L. Chatenoud. 2001. Tolerance to islet autoantigens in type 1 diabetes. Annu. Rev. Immunol. 19: 131-161. (Pubitemid 32368032)
25. Chatenoud, L., and J. A. Bluestone. 2007. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat. Rev. Immunol. 7: 622-632. (Pubitemid 47123550)
26. Dromey, J. A., B. H. Lee, H. Yu, H. E. Young, D. J. Thearle, K. P. Jensen, S. I. Mannering, and L. C. Harrison. 2011. Generation and expansion of regulatory human CD4(+) T-cell clones specific for pancreatic islet autoantigens. J. Autoimmun. 36: 47-55.
27. Herold, K. C., S. Gitelman, C. Greenbaum, J. Puck, W. Hagopian, P. Gottlieb, P. Sayre, P. Bianchine, E. Wong, V. Seyfert-Margolis, et al; Immune Tolerance Network ITN007AI Study Group. 2009. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin. Immunol. 132: 166-173.